A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Clinical trial NCT06163430 · RECRUITING
Trial details
- NCT number
- NCT06163430
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-26
- Primary completion
- 2029-11-30
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.